Будь ласка, використовуйте цей ідентифікатор, щоб цитувати або посилатися на цей матеріал: http://ir.librarynmu.com/handle/123456789/5835
Повний запис метаданих
Поле DCЗначенняМова
dc.contributor.authorOliynyk, O.-
dc.contributor.authorBarg, W.-
dc.contributor.authorSlifirczyk, A.-
dc.contributor.authorOliynyk, Y.-
dc.contributor.authorDubrov, S.-
dc.contributor.authorGurianov, V.-
dc.contributor.authorRorat, M.-
dc.date.accessioned2023-02-07T12:35:42Z-
dc.date.available2023-02-07T12:35:42Z-
dc.date.issued2021-
dc.identifier.urihttp://ir.librarynmu.com/handle/123456789/5835-
dc.description.abstractBackground: COVID-19-associated coagulopathy (CAC) exacerbates the course of coronavirus infection and contributes to increased mortality. Current recommendations for CAC treatment include the use of low-molecular weight heparins (LMWH) at prophylactic or therapeutic doses, as well as the use of unfractionated heparin (UFH). Methods: A randomised, controlled trial enrolled 126 patients hospitalised in the intensive care unit with severe COVID-19 complicated by CAC. The effects of LMWH at preventive and therapeutic doses and UFH at therapeutic doses on mortality and intubation rates were compared. Results: The number of intubations and deaths showed no significant difference depending on the anticoagulant therapy used. However, multivariate logistic regression models revealed an increased risk of intubation (p = 0.026, odds ratio (OR) = 3.33, 95% confidence interval (CI) 1.15–9.59), and an increased risk of death (p = 0.046, OR = 3.01, 95% CI 1.02–8.90), for patients treated with LMWH at a prophylactic dose but not at a therapeutic dose as compared to patients treated with UFH when controlling for other risk factors. Conclusions: The use of unfractionated heparin in the treatment of COVID-19-associated coagulopathy seems to be more effective at reducing the risk of intubation and death than enoxaparin at prophylactic doses.uk_UA
dc.language.isoenuk_UA
dc.subjectanticoagulant therapy; blood coagulation; SARS-CoV-2; respiratory failureuk_UA
dc.titleComparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathyuk_UA
dc.typeArticleuk_UA
Розташовується у зібраннях:Наукові публікації анестезіології та інтенсивної терапії

Файли цього матеріалу:
Файл Опис РозмірФормат 
Comparison of the Effect.pdf1,27 MBAdobe PDFПереглянути/Відкрити


Усі матеріали в архіві електронних ресурсів захищені авторським правом, всі права збережені.